|
1）Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology. 1981; 31: 51-7
|
|
|
|
2）Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep. 2003; 3: 64-9
|
|
|
|
|
|
3）Furuta A, Wakabayashi K, Haratake J, et al. Lysosomal storage and advanced senescence in the brain of LAMP-2-deficient Danon disease. Acta Neuropathol. 2013; 125: 459-61
|
|
|
|
|
|
4）Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009; 301: 1253-9
|
|
|
|
|
|
5）Huynh KK, Eskelinen EL, Scott CC, et al. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007; 26: 313-24
|
|
|
|
|
|
6）Schneede A, Schmidt CK, Holtta-Vuori M, et al. Role for LAMP-2 in endosomal cholesterol transport. J Cell Mol Med. 2011; 15: 280-95
|
|
|
|
|
|
7）Konecki DS, Foetisch K, Zimmer KP, et al. An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Biochem Biophys Res Commun. 1995; 215: 757-67
|
|
|
|
|
|
8）Eskelinen EL, Cuervo AM, Taylor MR, et al. Unifying nomenclature for the isoforms of the lysosomal membrane protein LAMP-2. Traffic. 2005; 6: 1058-61
|
|
|
|
|
|
9）Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996; 273: 501-3
|
|
|
|
|
|
10）Fujiwara Y, Furuta A, Kikuchi H, et al. Discovery of a novel type of autophagy targeting RNA. Autophagy. 2013; 9: 403-9
|
|
|
|
|
|
11）Fujiwara Y, Kikuchi H, Aizawa S, et al. Direct uptake and degradation of DNA by lysosomes. Autophagy. 2013; 9: 1167-71
|
|
|
|
|
|
12）Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000; 406: 906-10
|
|
|
|
|
|
13）Tanaka Y, Guhde G, Suter A, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature. 2000; 406: 902-6
|
|
|
|
|
|
14）Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002; 58: 1773-8
|
|
|
|
|
|
15）Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011; 13: 563-8
|
|
|
|
|
|
16）Schorderet DF, Cottet S, Lobrinus JA, et al. Retinopathy in Danon disease. Arch Ophthalmol. 2007; 125: 231-6
|
|
|
|
|
|
17）Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology. 2006; 113: 1010-3
|
|
|
|
|
|
18）Burusnukul P, de Los Reyes EC, Yinger J, et al. Danon disease: an unusual presentation of autism. Pediatr Neurol. 2008; 39: 52-4
|
|
|
|
|
|
19）Sugie K, Noguchi S, Kozuka Y, et al. Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies. J Neuropathol Exp Neurol. 2005; 64: 513-22
|
|
|
|
|
|
20）Ramachandran N, Munteanu I, Wang P, et al. VMA21 deficiency causes an autophagic myopathy by compromising V-ATPase activity and lysosomal acidification. Cell. 2009; 137: 235-46
|
|
|
|
|
|
21）Yamamoto A, Morisawa Y, Verloes A, et al. Infantile autophagic vacuolar myopathy is distinct from Danon disease. Neurology. 2001; 57: 903-5
|
|
|
|
|
|
22）Yan C, Tanaka M, Sugie K, et al. A new congenital form of X-linked autophagic vacuolar myopathy. Neurology. 2005; 65: 1132-4
|
|
|
|
|
|
23）Kaneda D, Sugie K, Yamamoto A, et al. A novel form of autophagic vacuolar myopathy with late-onset and multiorgan involvement. Neurology. 2003; 61: 128-31
|
|
|
|
|
|
24）Fukuda M, Viitala J, Matteson J, et al. Cloning of cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Comparison of their deduced amino acid sequences. J Biol Chem. 1988; 263: 18920-8
|
|
|
|
|
|
25）Eskelinen EL, Schmidt CK, Neu S, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol Cell. 2004; 15: 3132-45
|
|
|
|
|
|
26）Eskelinen EL, Illert AL, Tanaka Y, et al. Role of LAMP-2 in lysosome biogenesis and autophagy. Mol Biol Cell. 2002; 13: 3355-68
|
|
|
|
|
|
27）Saftig P, Beertsen W, Eskelinen EL. LAMP-2: a control step for phagosome and autophagosome maturation. Autophagy. 2008; 4: 510-2
|
|
|
|
|
|
28）Koga H, Cuervo AM. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis. 2011; 43: 29-37
|
|
|
|
|
|
29）Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305: 1292-5
|
|
|
|
|